Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA lifts partial clinical hold on vesigenurtucel-L

Feb. 11, 2016

Phase I data support progression of Immune Design's immuno-oncology candidates

Feb. 10, 2016

Adaptimmune's NY-ESO T-cell therapy earns FDA breakthrough therapy designation

Feb. 10, 2016

PDS Biotechnology and NCI to codevelop novel cancer immunotherapies

Feb. 10, 2016

OncoMed gives update on ALPINE and PINNACLE studies of tarextumab

Feb. 10, 2016

EBV-CTL granted U.S. orphan status for EBV-positive post-transplant lymphoproliferative disorders

Feb. 8, 2016

FDA awards breakthrough therapy designation to IMMU-132 for triple-negative breast cancer

Feb. 8, 2016

Blincyto increases overall survival compared with standard chemotherapy in B-cell ALL

Feb. 5, 2016

FDA grants fast track designation to TapImmune's TPIV-200 for ovarian cancer

Feb. 4, 2016

Heat Biologics provides update on its HS-410 phase II bladder cancer trial

Feb. 4, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...